Shattuck Labs, Inc.

NASDAQ:STTK

Biotechnology

Healthcare
$4.59 +2.33%

+$0.11 today

Market cap
$467.46M
Beta
1.09
P/E (TTM)
-10.9
EPS (TTM)
-$0.44
52W Low $0.71High $8.33

Volume 0.79M

Average 0.69M

STTK EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Shattuck Labs, Inc.NASDAQ: STTK

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA remains negative

Q1 FY2026 EBITDA was -$13.88M, compared with -$12.77M a year earlier. Trailing-twelve-month EBITDA was -$46.23M.

Context

  • EBITDA amounted to 4512.1% of revenue in FY2025, up 3260.9 pp from a year earlier.
  • EBITDA grew in size in 0 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 6 analysts of -$30.56M (+32.3%) for the fiscal year ending Dec 2026, a slowdown from the +37.0% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$13.88M-18.7% QoQ
Last fiscal yearDec 2025
-$45.12M+37.0% YoY
LTMMar 2026
-$46.23M+30.8% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-8.7%——
1 year+37.0%+32.3%-4.7 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(45.12M) USD
Year-over-year change
+37.0%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How STTK compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +30.8% is the 3rd highest of 10, against a peer median of -19.7%.
  • EBITDA amounts to 4623.1% of revenue for STTK, versus a peer median of 48.8%.
STTK Competitors
EBITDA for STTK and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PBYIPuma Biotechnology, Inc.LTM Mar 2026$44.91M USD-17.8%+34.6%19.8%
INDPIndaptus Therapeutics, Inc.LTM Mar 2026-$18.86M USD-19.7%——
PDSBPDS Biotechnology CorporationLTM Mar 2026-$27.92M USD+15.6%——
NBPNovaBridge BiosciencesLTM Sep 2025-CN¥33.25M CNY+92.9%——
SLSSELLAS Life Sciences Group, Inc.LTM Sep 2026-$35.76M USD-89.6%——
BDTXBlack Diamond Therapeutics, Inc.LTM Mar 2026-$38.09M USD-800.9%——
STTKShattuck Labs, Inc.LTM Mar 2026-$46.23M USD+30.8%—4623.1%
CBIOCrescent Biopharma, Inc.LTM Mar 2026-$158.86M USD-1227.0%—1336.8%
IOVAIovance Biotherapeutics, Inc.LTM Sep 2026-$185.11M USD+47.9%—48.8%
FTHFaeth Therapeutics, Inc.LTM Jun 2026-$195.4M USD-639.8%——
Peer median (excluding STTK) —-19.7%+34.6%48.8%

Competitors are the stored peer set for STTK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue30.02M652K1.66M5.72M1M
Cost of Revenue1.38M82.2M4.04M4.89M0
Gross Profit28.64M(81.55M)(2.39M)827K1M
Gross Margin95.4%-12507.2%-143.9%14.5%100.0%
Research & Development56.56M82.9M74.31M67.21M35.27M
Selling, General & Admin18.72M19.68M19.3M19.08M17.24M
Operating Expenses73.91M21.78M89.57M81.39M52.51M
Depreciation & Amortization1.38M3.07M4.04M3.83M3.69M
EBITDA(43.59M)(98.87M)(83.26M)(71.58M)(45.12M)
EBITDA Margin-145.2%-15164.4%-5024.5%-1251.2%-4512.1%
Operating Income(45.27M)(103.33M)(91.96M)(80.57M)(51.51M)
Operating Margin-150.8%-15848.0%-5549.6%-1408.3%-5150.8%
Interest Income625K1.59M4.67M5.17M2.7M
Interest Expense00000
Other Income / Expenses295K1.38M4.66M5.16M2.7M
Income Before Tax(44.97M)(101.95M)(87.3M)(75.41M)(48.81M)
Pre-Tax Margin-149.8%-15635.7%-5268.4%-1318.1%-4880.9%
Income Tax Expense00000
Net Income(44.97M)(101.95M)(87.3M)(75.41M)(48.81M)
Net Margin-149.8%-15635.7%-5268.4%-1318.1%-4880.9%
EPS (Basic)(1.07)(2.41)(2.05)(1.49)(0.70)
EPS (Diluted)(1.07)(2.41)(2.05)(1.49)(0.70)
Weighted Avg Shares42.03M42.38M42.6M50.76M69.58M
Weighted Avg Shares (Diluted)42.03M42.38M42.6M50.76M69.58M

Shattuck Labs, Inc.

NASDAQ:STTK

Intrinsic Alpha fair value

Locked

Current Price

$4.59

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.